Skip to content

Study · Not a test of the peptide alone · 2007

2 results

Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy.

Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martínez de Osaba MJ, Balasch J

Fertility and sterility13 Dec 2006Cited by 38 (Europe PMC)

PMID17173900 (opens in a new tab)DOI10.1016/j.fertnstert.2006.10.004 (opens in a new tab)PepBankPUB-17173900
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In young women receiving chemotherapy for Hodgkin's disease, all but three (10%) of those given triptorelin plus tibolone returned to spontaneous ovulation and menses, in contrast to 23% of control subjects (P<.05).

    In plain wordsIn women having chemotherapy for Hodgkin's disease, all but three given triptorelin plus tibolone regained ovulation and periods, in contrast to 23% of controls.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseReturn of spontaneous ovulation and menses
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Exceptions to return of spontaneous ovulation and menses
    3 patients
    triptorelin plus tibolone group
    Exceptions to return of spontaneous ovulation and menses
    10%
    triptorelin plus tibolone group
    Control group proportion reported in contrast
    23%
    control group

    Source sentences

    Summary
    In young women receiving chemotherapy for Hodgkin's disease, the combined use of triptorelin and tibolone cotreatment may be a useful tool for preserving ovarian function because all but three (10%) of the women in this treatment group returned to spontaneous ovulation and menses, in contrast to 23%…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In women receiving chemotherapy for Hodgkin's disease, bone mineral density did not differ significantly between triptorelin plus tibolone and controls.

    In plain wordsIn women receiving chemotherapy for Hodgkin's disease, bone density did not differ significantly between those given triptorelin plus tibolone and controls.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeBone mineral density
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    No significant differences were observed in bone mineral density between groups.
    1 context sentence
    Summary · context
    In young women receiving chemotherapy for Hodgkin's disease, the combined use of triptorelin and tibolone cotreatment may be a useful tool for preserving ovarian function because all but three (10%) of the women in this treatment group returned to spontaneous ovulation and menses, in contrast to 23%…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.